Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
CN Bio has received a grant from Innovate UK, the UK’s innovation agency, to develop human-relevant MPS to advance investigations into SARS-CoV-2 infection.
read more
Thursday, October 07, 2021
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the commercial launch of its Oncology Service in response to the global need to improve cancer ...
read more
CN Bio opened new contract research facilities at Cambridge Science Park. The Company’s laboratory space has been doubled in response to the increasing market demand for OOC services as the technology gains traction within drug discovery and ...
read more
Monday, December 04, 2023
CN Bio, a leading Organ-on-a-Chip (OOC) company specializing in designing and manufacturing single- and multi-organ microphysiological systems (MPS), has announced the pivotal role of its PhysioMimix® assay in affirming the effectiveness of INI-822. ...
read more
Tuesday, January 28, 2020
CNS announced Anthem Biosciences of Bangalore, India has completed a pilot run of the recrystallization of the Reata Pharmaceuticals API.
read more
Tuesday, November 26, 2019
CNS has entered into a sublicense agreement with WPD, a Polish corporation partially owned and controlled by Dr. Waldemar Priebe, the founder of the Company.
read more
Tuesday, February 04, 2020
CNS has completed the final GMP manufacturing run of its lead candidate Berubicin, which it acquired from Reata and the GMP material has met all specifications.
read more
Thursday, October 22, 2020
CNS announced the Company's U.S. manufacturer, Pii, has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate for GBM.
read more
CNS announced BSP has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme.
read more
CNS Pharmaceuticals has engaged Worldwide Clinical Trials as the contract research organization (CRO) for its upcoming Berubicin clinical trials.
read more
CoSara Diagnostics broke ground on the future Good Manufacturing Practices (GMP) facility in October 2017.
read more
Tuesday, November 07, 2017
Co-Diagnostics and Synbiotics announced CoSara Diagnostics, a Joint Venture for manufacturing, has broken ground for its manufacturing facility in India.
read more
FDA is alerting health care professionals to a voluntary recall of all non-expired products marketed as sterile made by Coastal Meds due to visible particles in some of the drug vials for injection.
read more
Cobra Biologics, a leading contract manufacturer of clinical and commercial scale biologics and pharmaceuticals, and targeted cancer therapy company BioCancell have announced an agreement to manufacture BioCancell’s BC-821 cancer drug for clinical ...
read more
Cobra Biologics, the international clinical and commercial manufacturer of biologics and pharmaceuticals and KAHR Medical Limited, that develops novel drugs based on the Signal Converter Proteins (SCP) technology for the treatment of cancer and ...
read more